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Abstract: Background: Recently, miRNA-181a2 could be identified as a major regulator of IDH1
expression in fat tissue. The IDH1 gene, its mutation and expression have a major impact on overall
survival in patients with glioblastoma. The presented study aimed to investigate the effect of miRNA-
181a2 on IDH1 expression in glioblastoma and on the prognosis of patients suffering from, for
example, a tumor. Methods: A total of 74 glioblastoma specimens were analyzed for the expression
of miRNA-181a2, acquired as fold change, using qRT-PCR. IDH1 protein expression was estimated
via mRNA quantification. Eight post mortal, non-glioma related brain tissue specimens served as
the control group. The results were correlated with relevant demographic and clinical aspects of
the cohort. A TCGA dataset was used as an independent reference. Results: MiRNA-181a2 was
significantly downregulated in tumor samples compared to the control group (p < 0.001). In the
glioblastoma cohort, 63/74 (85.1%) showed an IDH1 wild type, while 11/74 (14.9%) patients harbored
an IDH 1 mutation. In patients with IDH1 wild type glioblastoma, low miRNA-181a2 expression
correlated with a prolonged overall survival (p = 0.019), also verifiable in an independent TCGA
dataset. This correlation could not be identified for patients with an IDH1 mutation. MiRNA-181a2
expression tended to correlate inversely with IDH1 protein expression (p = 0.06). Gross total resection
of the tumor was an independent marker for a prolonged survival (p = 0.03). Conclusion: MiRNA-
181a2 seems to be a promising prognostic marker of selective glioblastoma patients with IDH1 wild
type characteristics. This effect may be mediated via direct regulation of IDH1 expression.
Keywords: microRNA; glioblastoma; prognosis; epigenetic; miR-181a2
1. Introduction
Glioblastoma (GBM) is a primary malignant brain tumor with a five-year survival
rate of less than 3% [1]. It is characterized by aggressive biological behavior and high
proliferation rates [2]. Currently, the gold-standard treatment for GBM combines surgical
gross total resection and concomitant radio-chemotherapy with temozolomide [3]. Relevant
factors that turned out to have impacted individual prognosis are age at diagnosis, extent of
resection, Karnofsky performance score and methylation status of the O6-Methylguanine-
DNA Methyltransferase (MGMT) promotor [4–6]. The most important molecular predictor
for survival is the mutation status of IDH1 and IDH2 within the tumor tissue [7]. Some
authors ascribe the effect of IDH1 (R132H) mutation (IDH1mut) on the clinical course
of glioma in general to the accumulation of 2-hydroxyglutarate in tumor cells [8]. This
metabolite is only produced in tumor cells harboring the IDH1 mutation, but not in cases of
IDH1 wild type (IDH1wt) [9]. In glioblastoma, IDH1 mutation, and therefore the potential
production of 2-hydroxyglutarate, may result in prolonged survival [7].
Processes 2021, 9, 728. https://doi.org/10.3390/pr9050728 https://www.mdpi.com/journal/processes
Processes 2021, 9, 728 2 of 11
Micro-RNAs (miRNA) are 20–25 base pairs long, single-stranded, non-coding RNAs,
which post-transcriptionally regulate gene expression. They do so via binding to a specific
messenger RNA (mRNA) of a transcripted gene. A perfect match of miRNA and mRNA
leads to the decay of the mRNA, whereas a sequential match is causing a blockade of
translation. In either case, this results in an impaired expression of the specific protein [10].
Exceptional expression of specific miRNAs in GBM has been proposed as a prognostic
marker for the clinical course of the disease [11].
The miRNA-181 family consists of six members, -181a1, -181a2, -181b1, -181b2, -181c
and -181d [12]. All members of this miRNA family seem to be downregulated in glioblas-
toma tissue compared to non-glioma related brain specimens [13]. Some of these miRNAs
have also been linked to glioma genesis, progression and the response to specific GBM
therapy strategies [14–16]. Moreover, miRNA-181a1 expression and connected methylation
pathways have been linked to prolonged survival in GBM patients [17].
Recently, miRNA-181a2 was identified to regulate IDH1 expression in fat tissue [18].
Therefore, and due to the known impact of IDH1 expression on the course of glioblastoma,
the question arises whether miRNA-181a2 expression itself also has an impact on prognosis.
2. Results
The expression level of miRNA-181a2 was assessed as fold change (FC), in relation to
miRNA standard RNU48, in all 74 tumor specimens. Subsequently, these findings were
correlated with clinical data, as well as the results of the methylation analysis of MGMT
and the mutation analysis of IDH1.
2.1. MiRNA-181a2 in the Whole Collective Compared Non Glioma Brain Tissue
The whole glioma collective (n = 74) was characterized by a FC of miRNA-181a2 of
0.031 ± 0.03, [0.002–0.241]. A specimen of non-glioma related brain tissue showed an
expression of FC = 0.15 ± 0.05 [0.09–0.24]. MiRNA-181a2 was significantly downregulated
in tumor samples compared to the control group (p < 0.001). This is highlighted in Figure 1.
There was no correlation of miRNA-181a2 expression with overall survival (OS) (p = 0.58)
and progression-free survival (PFS) (p = 0.62) regarding the whole collective of 74 patients.
MiRNA-181a2 level was also not associated with age at diagnosis (p = 0.48).
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Figure 1. MiRNA-181a2 expression in GBM specimen (green, n = 74) and non-glioma related brain
tissue of post mortal donors (blue, control group, n = 8) normalized to their respective RNU-48
expression. * indicates significance.
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2.2. MiRNA-181a2 in Subgroup Analysis IDH1wt Tumors
A stratified analysis was performed for 63 patients with IDH1wt tumors. This sub-
group showed an OS of 14.9 ± 15.6, [0.6–69.8] months. Progression-free survival was
9.3 ± 11.4, [0.2–58] months. Fold change of miRNA-181a2 expression was 0.026 ± 0.017,
[0.002–0.07]. When applying a model of linear regression, an inverse correlation between
expression of miRNA-181a2 and OS (p = 0.019) was observable. The same effect was seen
regarding miRNA-181a2 expression and PFS (p = 0.021), as visualized in Figure 2.
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2.3. MiRNA-181a2 in Subgroup Analysis IDH1mut Tumors
Data of 11 patients with an IDH1mut glioblastoma was further analyzed. This subgroup
showed an OS of 33.2 ± 33.1, [5.7–76.2] months. Progression-free survival was 11.1 ± 10.1,
[0.7–32.3] months. Fold change of miRNA-181a2 expression was 0.057 ± 0.06, [0.009–0.24].
There was no association between OS (p = 0.73) or PFS (p = 0.23) and the expression of
miRNA-181a2.




Figure 3. Kaplan-Meier curve of survival data for IDH1wt tumors. Overall survival (section A) and progression-free sur-
vival (section B) are shown for high (fold change FC ≥ 0.026, green curve) and low (FC < 0.026, blue curve) expression of 
miRNA-181a2. The X-axis represents time after diagnosis, and the Y-axis represents cumulative OS and PFS as appropri-
ate. Cum OS = cumulative overall survival; Cum PFS = cumulative progression-free survival. 
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2.4. MiRNA-181a2 Binding Site on mRNA of IDH1
To identify interactions of miRNA-181a2 and the mature mRNA sequence of IDH1, a
binding site analysis, via GenBank (https://www.ncbi.nlm.nih.gov/genbank/, accessed
on 1 March 2021), was performed. It revealed binding sites at nucleotide positions 449,
451–457, 460 and 468 in the mRNA sequence of IDH1. The binding configuration is of an
incomplete character. The results are shown in Figure 5.
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2.5. Effect of miRNA-181a2 Expression on IDH1 Expression
The impact of miRNA-181a2 on the prognosis of IDHwt tumors was evaluated by
IDH1 protein expression analysis. Indirect measurement via mRNA expression of IDH1
was used. Of all the 63 IDHwt tumors, 51 were analyzed for protein expression (81%).
Twelve cases had to be excluded of further analysis due to insufficient remaining tumor
tissu . Fold change of mRNA of IDH1 was 0.234 ± 0.309, [0.0002–1.12]. Applying a
model f line r regression, a trend (p = 0.06, R = −0.55) for an inverse correlation between
the xp ssion f miRNA-181a2 and mRNA expression of IDH1 could be id tifi d, as
highlighted in Figure 6. A high IDH1 protein expression seems to be linked to a low
miRNA-181a2 expression.
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2.6. Correlation with Further Clinical and Molecular Data in the Total Collective
IDH1 mutation correlated with a prolonged OS (p = 0.004) independently of miRNA-
181a2. Patients with an IDH1mut tumor survived 33.25 ± 33.12, [5.65–76.2] months. In
cases of an IDHWT tumor OS was 14.96 ± 15.59, [0.62–69.78] months.
MGMT promotor methylation was found in 37 (50%) of all cases. The residual 37 cases
(50%) showed no methylation. Patients harboring a MGMT methylation survived 20.76 ± 26.26,
[0.62–76.2] months. Those without an MGMT methylation survived 13.33 ± 12.55, [1.71–62.03]
months. This difference was statistically significant (p = 0.04).
The extent of resection was determined by postoperative magnetic resonance imaging
(MRI) within 48 h after surgery. A gross total resection (GTR) was defined as a lack of
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detectable tumor remnants. GTR was possible in 24/74 (33.8%) of the cases. If any residual
tumor was detectable, it was considered to be subtotal resection (STR). STR was identified
in 44/74 (59.5%). In 5/74 cases (6.7%), determination was not possible due to missing
postoperative MRI data. GTR was linked with prolonged overall survival (p = 0.03). Age
at diagnosis was an independent predictor of survival. Patients of higher age showed a
significantly decreased OS (p = 0.001).
2.7. Multivariate Analysis in the IDH1wt Cohort
The impact of miRNA-181a2 expression on survival in the IDH1wt cohort was even-
tually analyzed with respect to all the above-mentioned factors influencing survival. The
detailed results of a model of multivariate linear regression for OS are highlighted in Table 1.
MiRNA-181a2, age at diagnose, extend of resection as well as Karnofsky performance score
and MGMT methylation were significant and independent predictors for prolonged sur-
vival within the study population. MiRNA-181a2 expression was not associated with any
of the aforementioned clinical and molecular characteristics.
Table 1. Multivariate linear regression for OS in IDH1wt tumors.
Item Regression Coefficient Standard Error HR Sig. HR 95% Lower Range CI Upper
FC miRNA-181a2 −256.4 108.1 −2.37 0.021 * −472.7 −40.1
Extend of resection −0.95 0.97 −0.97 0.034 * −0.91 1.01
Age at diagnosis −0.48 0.173 −2.79 0.007 * −0.83 −0.14
MGMT −0.38 0.267 0.404 0.043 * 0.68 1.15
Karnofsky −0.33 0.009 0.97 0.001 * 0.95 0.96
* indicates significance.
3. Discussion
Members of the miRNA-181 family have been shown to impact glioma genesis, pro-
gression and the response to specific GBM therapy strategies [14–17]. MiRNA-181a1
overexpression was shown to sensitize glioma cells to radiation treatment due to the
downregulation of Bcl-2 expression [19]. Consecutively, miRNA-181a1 overexpression was
suggested as a positive prognostic marker in GBM [17]. MiRNA-181b1 and -181b2 have
been reported to function as tumor suppressors triggering growth inhibition, inducing
apoptosis and inhibiting invasion in glioma cells [20].
All members of this miRNA family seem to be downregulated in glioblastoma tissue,
as compared to a non-glioma related brain specimen [13]. This stands in concordance with
our findings as GBM specimen in the study at hand displayed a significant downregulation
of miRNA-181a2 compared to non-glioma brain tissue.
Irrespective of glioma specimen, literature refers to miRNA-181a2 as a regulator of
IDH1 expression in non-neoplastic tissue [18]. The impact of IDH1 itself on survival
in GBM is undisputed [21]. Main question of the study at hand was therefore whether
miRNA-181a2 impacts IDH1 expression in GBM and whether miRNA-181a2 expression
influences the clinical course of the disease, respectively.
In the study at hand, patients with IDH1wt GBM and a low miRNA-181a2 expression
showed a significant prolonged overall survival compared to patients with IDH1wt tumors
and a high miRNA-181a2 expression, also verifiable in an independent TCGA cohort.
This effect of miRNA-181a2 demonstrated to be independent of other factors influencing
survival in GBM in multivariate analysis. Interestingly no such effect was noticed within
the group of patients suffering from an IDH1mut GBM. The authors are aware of a certain
limitation resulting from the limited number of cases within the TCGA cohort with 32 pa-
tients and the IDHmut sub-cohort with only 11 individuals. Since a reliable correlation is
based on highly specific parameters, as mentioned above, potential reference cases of the
TCGA database turned out to be as limited as presented.
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The impact of IDH1 mutation on GBM prognosis is commonly attributed to the ac-
cumulation of an onco-neo-metabolite in IDH1mut cases. IDH1, soluted in the cytoplasm,
catalyzes the oxidative decarboxylation of isocitrate for α-ketoglutarate in the citric acid
cycle [22]. It therefore plays a crucial role in the energy metabolism of the cell. All cells,
including tumor cells, require a functional IDH1 for survival and reproduction [23]. A mu-
tation (R132H) of IDH1 in glioma cells prevents catalyzation of isocitrate to α-ketoglutarate.
Instead IDH1mut catalyzes isocitrate to 2-hydoxyglutarate (2HG). This new metabolite
cannot be further processed in the citrate cycle and therefore accumulates in GBM cells
causing multiple epigenetic transitions, resulting in a less aggressive or invasive tumor
compared to its IDH wildtype counterpart [8].
While the effect of miRNA-181a2 on prognosis in our study was only observed in
IDHwt tumors, 2HG expression may not have contributed to this effect as 2HG produc-
tion is strictly bound to the IDH1 R132H mutation. This may be a hint that other IDH1
related mechanisms next to 2HG production in IDH1mut GBM cases may play a role in
the progression of the disease. Hence the question arose, if IDH1 expression, independent
of the R132H mutation and its consecutive accumulation of 2HG, may be regulated by
miRNA-181a2.
The study at hand indicates a trend, that miRNA-181a2 inversely correlates with IDH1
expression in GBM. The authors are aware that the method used, measuring the IDH1
protein expression via its mRNA expression, has its limitations due to its indirect nature.
Results may be biased due to a post-transcriptional mRNA modification, leading to an over-
or underestimation of the corresponding IDH1 protein expression [24]. The reason for using
this method despite its disadvantages was the lack of sufficient tumor material for further
proteomic analysis. Hence, RNA isolates, initially used for miRNA expression acquisition,
were used for protein expression analysis. In respect to the above-mentioned drawbacks,
the presented results of the miRNA-181a2 impact on IDH1 protein expression should be
scrutinized critically. Nevertheless, they are in line with the literature, as demonstrated in
fat tissue [18].
After all, the data in the presented study offers a new perspective regarding IDH1
impact on GBM. Not only the catalyzation of 2HG in IDH1mut GBM cases may influence
prognosis, but also miRNA-181a2 expression in their IDH1wt counterparts, regulating the
very expression of IDH1 itself.
Further factors associated with OS and PFS were the age at diagnosis and the extent
of tumor resection. In the study at hand, older patients had a significantly decreased
OS. This aligns with other authors who reported a significantly reduced survival in older
glioblastoma patients [25,26].
In the present study, patients undergoing GTR had a significantly longer OS, compared
to those who only had STR. The positive prognostic effect of GTR was also independent
of miRNA-181a2 expression in multivariate analysis. This finding, which is supported by
multiple reports in the literature, underlines the tremendous importance of radical surgery
in GBM treatment [27,28].
A limitation of the study is its retrospective design and the limited number of patients
included especially regarding analysis of IDH1 protein expression. This is of importance
regarding the considerable spread in the expression levels of the analyzed RNAs. However,
these findings may be ascribable to the very nature of GBM disease. As the heterogeneity
of this tumor entity is well known, widespread expression levels of district miRNAs may
be a facsimile of this characteristic on an epigenetic level.
In conclusion, a low miRNA-181a2 expression seems to ameliorate prognosis in GBM
IDH1wt patients—at least partly—via IDH1 regulation. In addition, this could enable a
new therapeutic approach as, at least theoretically, miRNA-181a2 expression in tumors can
be downregulated via an anti-miRNA-181a2 drug.
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4. Methods
4.1. Patients
Inclusion criteria were defined as neuropathologically approved diagnosis of primary
GBM, as well as the availability of sufficient tumor tissue for further analysis. The probes
collected were graded by the current WHO classification of brain tumors. Specimens of
74 cases where included. Informed consent was given by all participants of the study. All
patients underwent surgery with consecutive concomitant radio-chemotherapy (Stupp-
Scheme) in our center between 2014 and 2018 with clinical follow-up available until 2020.
Clinical data regarding the cohort is given in Table 2.
Table 2. Patient baseline characteristics and treatment details (SD = standard deviation).
All Patients, (n = 74)
Mean age ± SD, [range] in years 59.1 ± 11.4, [35.7–83.2]




MGMT status, No, (%)
methylated 35, (47.3)
unmethylated 39, (52.7)
IDH1 status, No, (%)
R132H mutation 11, (14.9)
Wild type 63, (85.1)
Extent of resection, No, (%)
Gross total resection 25, (33.8)
Subtotal resection 44, (59.5)
Not available 5, (6.8)
Overall survival ± SD, [range] in month 17.7 ± 19.9, [0.6–76.2]
Progression-free survival ± SD, [range] in month 9.5 ± 11.2, [0.2–58]
Death by end of trial, No, (%) 72, (97.3)
Eight brain tissue probes deriving from patients who faded away not related with
glioma were provided by the anatomical institute of Saarland University (control group).
Informed and written consent for postmortal scientific use of the tissue was obtained from
all donors. All specimens were collected from the primary motoric cortex within less
than 12 h after death as recommended by literature [29–31]. All tumor specimens were
snap frozen after removal and stored at −80 ◦C prior to further analysis. This study was
approved by the local ethics commission (93/16).
4.2. MiRNA Analysis
Isolation of miRNA from tumor specimens was performed using a miRNeasy miRNA
Isolation kit (Qiagen, Venlo, The Netherlands) according to the manufacturer’s instructions.
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was performed
using an ABI 7900 real-time PCR system (Applied Biosystems, Waltham, MA, USA).
Primers for miRNA-181a2 for TaqMan miRNA assays were purchased from Applied
Biosystems (TaqMan MicroRNA Assay, ID 002317, Applied Biosystems, Waltham, MA,
USA). A Transcription Kit for reverse transcription (Applied Biosystems, Waltham, MA,
USA) and TaqMan Gene Expression Master Mix for quantitative real-time PCR (Applied
Biosystems, Waltham, MA, USA) were used according to the manufacturer’s protocol. PCR
was conducted in triplicate including negative controls. Quantitative miRNA expression
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data were calculated using the comparative CT method with RNU48 as an accredited and
stable reference miRNA [32]. For miRNA-181a2, fold change (FC) was calculated as follows:
FC = 2− (CT-miRNA-181a2 − CT-RNU48). The expression of miRNA-181a2 was normalized to
RNU48. A miRNA-181a2 expression simmilar to RNU48 expression within the same
specimen is rated 1.
4.3. IDH1 Protein Expression Analysis
Messenger-RNA (mRNA) expression of IDH1 was used as an indirect method to
estimate the protein expression of IDH1. For these analyses, the RNA specimens ac-
quired by miRNA isolation were used. Again, quantitative reverse transcription PCR was
performed to analyze the expression values (TaqMan Gene Expression Assay, IDH1: ID
Hs01855675_s1, and β-actin: ID Hs99999903). Reverse transcription was performed with
random primers (High-Capacity cDNA Reverse Transcription Kit, Applied Biosystems).
Quantitative mRNA expression data was calculated with β-actin as reference RNA. FC
was calculated, as described before [11].
4.4. Methylation Analysis and IDH1-R123H Staining
MGMT was determined by methylation-specific polymerase chain reaction (MS-PCR),
as described previously [33]. Immunohistochemistry for IDH1 mutation was conducted, as
described previously [11].
4.5. TCGA Data
To obtain data for an independent cohort, miRNA-181a2 expression data from TCGA
was downloaded via the xenabrowser platform (https://xenabrowser.net/, accessed
1 March 2021). In these experiments, miRNA expression was measured with microar-
rays (Agilent Human miRNA_8 x 15K). The dimensionless fluorescence signal captured
on the microarrays was normalized to that of the TCGA project (so-called level 3 data) to
facilitate relative comparisons of expression levels between specimen. Survival data was
obtained via the same platform. In total, TCGA contained 671 GBM datasets. A subset
of 32 patients meet the criteria of primary GBM, available miRNA-181a2 expression data,
a IDH1wt, as well as a documented therapy protocol. All patients in this subset received
a concomitant radio-chemotherapy with temozolomide. Kaplan–Meier survival analysis
was performed by stratifying the expression values of these 32 patients by the median
miRNA-181a2 expression into high (≥median, 16 patients) and low (<median, 16 patients)
expression categories.
4.6. Statistical Analysis
All statistical analyses were performed using SPSS v.23 (IBM, Armonk, NY, USA). A
model of linear regression was used to analyze the correlation between miRNA expression
and clinical parameters such as overall survival, progression-free survival, and age at disease
onset. Progression was defined either radiologically as a new contrast dye enhancing tumor
formation or death of the patient. Cox regression was used to analyze overall survival and
progression-free survival. Potentially interfering clinical characteristics like the extent of
resection, age at diagnosis and Karnofsky performance sore were considered for final analysis.
A value of p < 0.05 was considered statistically significant. A value of p < 0.10 was considered
to be a statistical trend. Standard deviation was presented by ± [15].
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